11,376 Shares in DaVita Inc. (NYSE:DVA) Acquired by Natixis

Natixis bought a new stake in DaVita Inc. (NYSE:DVA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 11,376 shares of the company’s stock, valued at approximately $1,701,000.

A number of other large investors also recently added to or reduced their stakes in DVA. Te Ahumairangi Investment Management Ltd raised its holdings in shares of DaVita by 1.0% in the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 48,137 shares of the company’s stock valued at $7,846,000 after buying an additional 500 shares during the period. Tidal Investments LLC grew its position in DaVita by 45.2% in the 3rd quarter. Tidal Investments LLC now owns 5,688 shares of the company’s stock valued at $932,000 after acquiring an additional 1,771 shares in the last quarter. Franklin Resources Inc. increased its stake in DaVita by 134.6% during the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company’s stock worth $8,885,000 after purchasing an additional 31,502 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after purchasing an additional 92,014 shares during the period. Finally, Versant Capital Management Inc grew its holdings in shares of DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after purchasing an additional 169 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on DVA shares. Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Thursday, April 10th. Finally, Barclays raised their target price on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $166.33.

DaVita Stock Up 1.1 %

Shares of NYSE:DVA opened at $134.95 on Wednesday. The firm has a 50 day simple moving average of $147.51 and a 200-day simple moving average of $155.64. DaVita Inc. has a twelve month low of $130.96 and a twelve month high of $179.60. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The company has a market capitalization of $10.80 billion, a PE ratio of 12.57, a P/E/G ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, equities analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.